ANAB
AnaptysBio, Inc.
NASDAQ · USHealthcareBiotechnology
$50.29-13.29%
Price as of Jul 20, 2026
ANAB financials
AnaptysBio, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M |
| Cost of revenue | $2.4M | $163.8M | $132.3M | $88.8M |
| Gross profit | $232.2M | -$72.6M | -$115.1M | -$78.5M |
| Operating expenses | $184.3M | $42.4M | $49.3M | $36.6M |
| Operating income | $47.9M | -$114.9M | -$164.4M | -$115.2M |
| Net income | -$13.2M | -$145.2M | -$163.6M | -$128.7M |
| EBITDA | $69.2M | -$92.7M | -$156.4M | -$105.3M |
| Basic EPS | $-0.46 | $-5.12 | $-6.08 | $-4.57 |
| Diluted EPS | $-0.46 | $-5.12 | $-6.08 | $-4.57 |
| Balance sheet | ||||
| Cash & equivalents | $238.2M | $123.1M | $36.0M | $71.3M |
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M |
| Total liabilities | $327.2M | $413.0M | $364.3M | $348.3M |
| Stockholders’ equity | $37.2M | $70.9M | $88.1M | $262.1M |
| Total debt | $14.1M | $369.5M | $17.8M | $19.4M |
| Net debt | -$224.1M | $246.4M | -$18.2M | -$51.9M |
| Cash flow | ||||
| Operating cash flow | $19.7M | -$135.3M | -$120.8M | -$73.6M |
| Capital expenditure | -$87.0K | -$358.0K | -$807.0K | -$358.0K |
| Free cash flow | $19.6M | -$135.7M | -$121.6M | -$74.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$68.6M | -$456.0K | -$50.0M | $0.00 |